LT5143B - Monoamino sunaudojimo slopintojas - Google Patents

Monoamino sunaudojimo slopintojas Download PDF

Info

Publication number
LT5143B
LT5143B LT2003075A LT2003075A LT5143B LT 5143 B LT5143 B LT 5143B LT 2003075 A LT2003075 A LT 2003075A LT 2003075 A LT2003075 A LT 2003075A LT 5143 B LT5143 B LT 5143B
Authority
LT
Lithuania
Prior art keywords
methyl
phenyl
oxy
aminopropane
compound
Prior art date
Application number
LT2003075A
Other languages
English (en)
Lithuanian (lt)
Other versions
LT2003075A (en
Inventor
Edward Luis Mattiuz
John-Michael Sauer
William Joe Wheeler
David Taiwai Wong
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23045157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT5143(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of LT2003075A publication Critical patent/LT2003075A/xx
Publication of LT5143B publication Critical patent/LT5143B/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
LT2003075A 2001-03-06 2003-08-11 Monoamino sunaudojimo slopintojas LT5143B (lt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27373001P 2001-03-06 2001-03-06

Publications (2)

Publication Number Publication Date
LT2003075A LT2003075A (en) 2004-03-25
LT5143B true LT5143B (lt) 2004-06-25

Family

ID=23045157

Family Applications (1)

Application Number Title Priority Date Filing Date
LT2003075A LT5143B (lt) 2001-03-06 2003-08-11 Monoamino sunaudojimo slopintojas

Country Status (35)

Country Link
US (2) US20040082666A1 (fr)
EP (1) EP1379492B1 (fr)
JP (1) JP2004525912A (fr)
KR (1) KR20030092012A (fr)
CN (1) CN1229331C (fr)
AP (1) AP2003002855A0 (fr)
AT (2) AT414238B (fr)
AU (1) AU2002245385B2 (fr)
BR (1) BR0207716A (fr)
CA (1) CA2440161A1 (fr)
CH (1) CH695982A5 (fr)
CZ (1) CZ20032380A3 (fr)
DE (1) DE60226715D1 (fr)
DK (1) DK200301267A (fr)
EA (1) EA005768B1 (fr)
EC (1) ECSP034760A (fr)
EE (1) EE200300419A (fr)
ES (2) ES2201942B2 (fr)
FI (1) FI20031191A (fr)
GB (1) GB2389851B (fr)
HR (1) HRP20030710A2 (fr)
HU (1) HUP0303341A3 (fr)
IL (1) IL157779A0 (fr)
LT (1) LT5143B (fr)
LU (1) LU91038B1 (fr)
LV (1) LV13119B (fr)
NO (1) NO20033921L (fr)
NZ (1) NZ527431A (fr)
OA (1) OA12494A (fr)
PL (1) PL363840A1 (fr)
SE (1) SE526598C2 (fr)
SK (1) SK10632003A3 (fr)
TR (1) TR200705146T1 (fr)
WO (1) WO2002070457A1 (fr)
ZA (1) ZA200306882B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0303341A3 (en) * 2001-03-06 2007-03-28 Lilly Co Eli Inhibitor of monoamine uptake and pharmaceutical compositions containing it
WO2005020976A2 (fr) * 2003-08-27 2005-03-10 Eli Lilly And Company Traitement des troubles profonds du developpement au moyen d'inhibiteurs de la recapture de la norepinephrine
CA2548304A1 (fr) * 2003-12-12 2005-07-07 Eli Lilly And Company Traitement des bouffees de chaleur, des troubles du controle des impulsions et du changement de personnalite consecutifs a un etat pathologique general
WO2011027359A2 (fr) * 2009-07-30 2011-03-10 Matrix Laboratories Ltd Nouveau procédé de préparation de 4-hydroxy atomoxétine
WO2012020418A1 (fr) 2010-08-12 2012-02-16 Matrix Laboratories Ltd Nouveaux polymorphes de chlorhydrate de 4-hydroxy-atomoxétine
DE102013022397A1 (de) 2013-12-19 2016-07-07 Metrax Gmbh Vorrichtung zur Unterstützung eines Ersthelfers bei der Herzdruckmassage
GR1008819B (el) 2015-05-22 2016-08-01 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
CN107935848B (zh) * 2017-11-21 2020-12-22 中国农业科学院兰州畜牧与兽药研究所 一种六茜素衍生物及其制备方法和应用
MX2021004883A (es) * 2018-10-31 2021-08-05 Apnimed Inc Delaware Metodos y composiciones para tratar apnea del sue?o.

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
EP0909754A1 (fr) 1997-10-14 1999-04-21 Eli Lilly And Company Procédé pour préparar des composés chiraux
WO2000058262A1 (fr) 1999-03-29 2000-10-05 Eli Lilly And Company Procedes stereospecifiques de preparation de la tomoxetine et de ses intermediaires
WO2000061540A1 (fr) 1999-04-09 2000-10-19 Eli Lilly And Company Procedes de preparation de 3-aryloxy-3-arylpropylamines et de leurs produits intermediaires

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2432500A1 (fr) * 1978-02-24 1980-02-29 Roussel Uclaf Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
US5112619A (en) * 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
ZA885824B (en) * 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
PH30083A (en) * 1991-02-25 1996-12-27 Lilly Co Eli Treatment of lower urinary tract disorders
EA200300567A1 (ru) * 2000-11-15 2004-10-28 Эли Лилли Энд Компани Лечение состояний тревоги
HUP0303341A3 (en) * 2001-03-06 2007-03-28 Lilly Co Eli Inhibitor of monoamine uptake and pharmaceutical compositions containing it

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4018895A (en) 1974-01-10 1977-04-19 Eli Lilly And Company Aryloxyphenylpropylamines in treating depression
US4194009A (en) 1974-01-10 1980-03-18 Eli Lilly And Company Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5023269A (en) 1986-12-22 1991-06-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
EP0909754A1 (fr) 1997-10-14 1999-04-21 Eli Lilly And Company Procédé pour préparar des composés chiraux
WO1999018947A1 (fr) 1997-10-14 1999-04-22 Eli Lilly And Company Procede de preparation de composes chiraux
WO2000058262A1 (fr) 1999-03-29 2000-10-05 Eli Lilly And Company Procedes stereospecifiques de preparation de la tomoxetine et de ses intermediaires
WO2000061540A1 (fr) 1999-04-09 2000-10-19 Eli Lilly And Company Procedes de preparation de 3-aryloxy-3-arylpropylamines et de leurs produits intermediaires

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
E.J COREY, GREGORY A REICHARD: "Enantioselective and practical syntheses of R- and S-fluoxetines", TETRAHEDRON LETTERS, 1989, pages 5207, XP002112223, DOI: doi:10.1016/S0040-4039(01)93743-8
GREEN, WUTZ: "Protecting Groups in Chemical Synthesis (3nd ed.)"
THOMAS M. KOENIG, DAVID MITCHELL: "A convenient method for preparing enantiomerically pure norfluoxetine, fluoxetine and tomoxetine", TETRAHEDRON LETTERS, 1994, pages 1339, XP002121949, DOI: doi:10.1016/S0040-4039(00)76212-5
Y. GAO, K. B. SHARPLESS: "Asymmetric synthesis of both enantiomers of tomoxetine and fluoxetine. Selective reduction of 2,3-epoxycinnamyl alcohol with Red-Al", J. ORG. CHEM., 1988, pages 4084

Also Published As

Publication number Publication date
JP2004525912A (ja) 2004-08-26
HUP0303341A2 (hu) 2004-01-28
ATE396170T1 (de) 2008-06-15
NZ527431A (en) 2005-05-27
GB2389851B (en) 2005-05-25
ECSP034760A (es) 2003-10-28
US7384983B2 (en) 2008-06-10
TR200705146T1 (tr) 2008-02-21
SE526598C2 (sv) 2005-10-18
LV13119B (en) 2004-06-20
SK10632003A3 (sk) 2004-06-08
EE200300419A (et) 2004-02-16
ES2201942B2 (es) 2004-12-16
GB0323169D0 (en) 2003-11-05
AP2003002855A0 (en) 2003-08-20
EP1379492B1 (fr) 2008-05-21
DK200301267A (da) 2003-11-06
PL363840A1 (en) 2004-11-29
NO20033921L (no) 2003-11-05
CN1494526A (zh) 2004-05-05
SE0302361L (sv) 2003-09-03
ES2305221T3 (es) 2008-11-01
WO2002070457A1 (fr) 2002-09-12
US20040082666A1 (en) 2004-04-29
LU91038B1 (fr) 2003-09-11
CZ20032380A3 (en) 2004-03-17
CH695982A5 (de) 2006-11-15
US20050209341A1 (en) 2005-09-22
LT2003075A (en) 2004-03-25
ZA200306882B (en) 2004-12-03
EP1379492A1 (fr) 2004-01-14
FI20031191A (fi) 2003-08-25
AU2002245385B2 (en) 2007-01-18
GB2389851A (en) 2003-12-24
HUP0303341A3 (en) 2007-03-28
NO20033921D0 (no) 2003-09-04
DE60226715D1 (de) 2008-07-03
CN1229331C (zh) 2005-11-30
AT414238B (de) 2006-10-15
ATA90422002A (de) 2006-01-15
ES2201942A1 (es) 2004-03-16
OA12494A (en) 2006-05-24
EA200300978A1 (ru) 2004-02-26
BR0207716A (pt) 2004-03-23
KR20030092012A (ko) 2003-12-03
SE0302361D0 (sv) 2003-09-03
IL157779A0 (en) 2004-03-28
WO2002070457A8 (fr) 2004-06-03
HRP20030710A2 (en) 2004-08-31
EA005768B1 (ru) 2005-06-30
CA2440161A1 (fr) 2002-09-12

Similar Documents

Publication Publication Date Title
US7384983B2 (en) Inhibitor of monoamine uptake
JP4833884B2 (ja) ３，３−ジフェニルプロピルアミンの新規な誘導体
TWI436762B (zh) 二環性γ－胺基酸衍生物
US11905276B2 (en) Bicyclic compound that acts as CRBN protein regulator
KR100192622B1 (ko) 페네타놀아민 화합물
AU2002245385A1 (en) Inhibitor of monoamine uptake
US20240115710A1 (en) Synthesis routes to access mdma prodrugs by using controlled and non-controlled intermediates
US8232405B2 (en) Benzylpiperizine compound
CN115894456A (zh) 一种氘代吡唑氨基嘧啶类化合物、药物组合物和用途
AU2007201684A1 (en) Inhibitor of monoamine uptake
PT97858A (pt) Metodo para a preparacao de um composto dicloroanilina tendo um substituinte contendo um grupo piridinilo
JP2022515156A (ja) ボリナンセリンの重水素化形態および誘導体
US7183319B2 (en) Phenylethylamine derivatives and their use in the treatment of melanoma
US20240122876A1 (en) Compositions and methods for the treatment of ocular disorders
JP2772650B2 (ja) 新規化合物およびその医薬的用途
US20110118358A1 (en) Deuterium-enriched salmeterol